Caplin Point Lab scales record high after robust Q4 outcome

Caplin Point Laboratories surged 8.73% at Rs 1,473 at 14:49 IST on BSE, after consolidated net profit surged 81.8% to Rs 12.69 crore on 46.2% growth in net sales to Rs 70.13 crore in Q4 June 2015 over Q4 June 2014.

Caplin Point Laboratories announced Q4 result after market hours yesterday, 20 August 2015.

Meanwhile, the S&P BSE Sensex was down 293.33 points or 1.06% at 27,314.49

On BSE, so far 69,413 shares were traded in the counter as against average daily volume of 9,592 shares in the past one quarter.

The stock hit a high of Rs 1,522.75 so far during the trading session, which is a record high for the counter. The stock hit a low of Rs 1,356.50 so far during the day. The stock had hit a 52-week low of Rs 337 on 21 October 2013.

The stock had outperformed the market over the past one month till 20 August 2015, falling 0.95% compared with 2.86% fall in the Sensex. The scrip also outperformed the market in past one quarter, gaining 39.81% as against Sensex's 0.82% decline.

The small-cap company has equity capital of Rs 15.11 crore. Face value per share is Rs 10.

Caplin Point Laboratories currently has three fully functioning facilities and one more facility in the pipeline, capable of manufacturing a wide range of dosage forms and products catering to all segments of the pharmaceutical industry.

Powered by Capital Market - Live News